GT200900089A - Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine - Google Patents

Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine

Info

Publication number
GT200900089A
GT200900089A GT200900089A GT200900089A GT200900089A GT 200900089 A GT200900089 A GT 200900089A GT 200900089 A GT200900089 A GT 200900089A GT 200900089 A GT200900089 A GT 200900089A GT 200900089 A GT200900089 A GT 200900089A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical composition
modified release
nsaid
muscle relaxant
coated microspheres
Prior art date
Application number
GT200900089A
Other languages
English (en)
Inventor
Garcia Salgado Lopez Enrique Raul
Arzola Paniagua Angelica
Poot Lopez Luis Fernando
Escorcia Rodriguez Francisco
Barrango Hernandez Gustavo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900089A publication Critical patent/GT200900089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA DE LIBERACIÓN MODIFICADA EN CÁPSULAS CON MICROESFERAS RECUBIERTAS QUE COMPRENDE LA COMBINACIÓN DE DOS PRINCIPIOS ACTIVOS DE TIEMPOS DE CONCENTRACIÓN PLASMÁTICA RADICALMENTE DIFERENTES, ÉSTOS SON UN MÚSCULO RELAJANTE (TIZANIDINA) Y UN ANALGÉSICO ANTIINFLAMATORIO NO ESTEROIDE (MELOXICAM), VEHÍCULOS O EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES; ASÍ COMO A UN PROCESO PARA LA MANUFACTURA DE LA COMPOSICIÓN Y AL USO DE DICHA COMBINACIÓN PARA LA PREPARACIÓN DE UN MEDICAMENTO CON ACTIVIDAD TERAPÉUTICA SINÉRGICA INDICADA EN EL TRATAMIENTO DE ESPASTICIDAD, DESÓRDENES RELACIONADOS CON PADECIMIENTOS MUSCULARES Y/O MÚSCULO ESQUELÉTICO Y DOLOR EN GENERAL DE MODERADO A SEVERO.
GT200900089A 2006-10-18 2009-04-17 Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine GT200900089A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06012024 2006-10-18

Publications (1)

Publication Number Publication Date
GT200900089A true GT200900089A (es) 2012-01-13

Family

ID=39313650

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900089A GT200900089A (es) 2006-10-18 2009-04-17 Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine

Country Status (16)

Country Link
US (1) US20100166856A1 (es)
EP (1) EP2085076B1 (es)
AR (1) AR073435A1 (es)
AT (1) ATE499089T1 (es)
BR (1) BRPI0718368A2 (es)
CA (1) CA2670690C (es)
CL (1) CL2007002975A1 (es)
CO (1) CO6140021A2 (es)
CR (1) CR10801A (es)
DE (1) DE602007012751D1 (es)
EC (1) ECSP099348A (es)
ES (1) ES2361883T3 (es)
GT (1) GT200900089A (es)
PE (1) PE20081464A1 (es)
UY (1) UY30636A1 (es)
WO (1) WO2008047208A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
BR112012008317A2 (pt) * 2009-09-17 2016-03-22 Upsher Smith Lab Inc produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
PL2338473T3 (pl) 2009-12-18 2017-07-31 Mdm S.P.A. Postacie farmaceutycznej dawki tizanidyny i drogi jej podawania
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
NZ701190A (en) * 2012-04-27 2016-07-29 Troy Lab Pty Ltd Combination meloxicam and xylazine therapy in animals
EP2977045A1 (en) * 2014-07-21 2016-01-27 Sanovel Ilac Sanayi ve Ticaret A.S. Zaltoprofen and muscle relaxant combinations
US10813916B2 (en) * 2015-05-29 2020-10-27 Jubilant Generics Limited Immediate release pharmaceutical composition of tizanidine
US20190060287A1 (en) * 2017-08-28 2019-02-28 Adare Pharmaceuticals, Inc. Tizanidine formulations
CN113398096A (zh) * 2021-06-27 2021-09-17 烟台大学 一种含有美洛昔康的长效注射微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
KR100507946B1 (ko) * 2001-01-31 2005-08-17 룀 게엠베하 운트 콤파니 카게 상이하게 피복된 펠렛 형태를 두 가지 이상 포함하는 다중 입상형 약제
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
US8502335B2 (en) 2009-07-29 2013-08-06 Taiwan Semiconductor Manufacturing Company, Ltd. CMOS image sensor big via bonding pad application for AlCu Process

Also Published As

Publication number Publication date
CL2007002975A1 (es) 2008-01-04
EP2085076A4 (en) 2010-03-17
EP2085076B1 (en) 2011-02-23
CO6140021A2 (es) 2010-03-19
ECSP099348A (es) 2009-06-30
UY30636A1 (es) 2008-05-02
DE602007012751D1 (de) 2011-04-07
ES2361883T3 (es) 2011-06-24
CR10801A (es) 2009-07-03
US20100166856A1 (en) 2010-07-01
PE20081464A1 (es) 2008-12-31
CA2670690C (en) 2014-12-30
ATE499089T1 (de) 2011-03-15
EP2085076A1 (en) 2009-08-05
WO2008047208A1 (es) 2008-04-24
CA2670690A1 (en) 2008-04-24
AR073435A1 (es) 2010-11-10
BRPI0718368A2 (pt) 2013-11-12

Similar Documents

Publication Publication Date Title
GT200900089A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine
Falcon et al. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice
Perez-Lloret et al. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease
Colla et al. Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice
Molina-Hernández et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists
Trujillo et al. Increased response to ketamine following treatment at long intervals: implications for intermittent use
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
JP2007536311A5 (es)
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
PT1691811E (pt) Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
NZ702485A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
Salamone et al. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism
SV2009003288A (es) Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
RU2014129508A (ru) Новая комбинация
TNSN07474A1 (en) Dosage regimen for prasugrel
Ionescu et al. Current trends in identifying rapidly acting treatments for depression
Carreno et al. Ketamine: Leading us into the future for development of antidepressants
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
Le Roy et al. A polyamine-deficient diet opposes hyperalgesia, tolerance and the increased anxiety-like behaviour associated with heroin withdrawal in rats